KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBITDA: 2013-2025

Historic EBITDA for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.5 million.

  • Xenon Pharmaceuticals' EBITDA fell 52.82% to -$90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$316.0 million, marking a year-over-year decrease of 43.05%. This contributed to the annual value of -$279.3 million for FY2024, which is 30.48% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' EBITDA is -$90.5 million, which was down 8.09% from -$83.8 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year EBITDA high stood at -$15.6 million for Q3 2021, and its period low was -$90.5 million during Q3 2025.
  • Over the past 3 years, Xenon Pharmaceuticals' median EBITDA value was -$58.4 million (recorded in 2024), while the average stood at -$61.3 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' EBITDA plummeted by 3,382.66% in 2021 and then increased by 14.28% in 2022.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' EBITDA stood at -$24.8 million in 2021, then plummeted by 74.45% to -$43.3 million in 2022, then fell by 23.92% to -$53.7 million in 2023, then plummeted by 44.29% to -$77.5 million in 2024, then slumped by 52.82% to -$90.5 million in 2025.
  • Its last three reported values are -$90.5 million in Q3 2025, -$83.8 million for Q2 2025, and -$64.3 million during Q1 2025.